Value-based pricing should be fully integrated with an evolved Pharmaceutical Price Regulation Scheme for existing products, according to the Association of the British Pharmaceutical Industry. This should be created jointly by the Government and the pharmaceutical industry as part of a voluntary agreement. The ABPI also says in its response to the Government's consultation on value-based pricing that the NHS Commissioning Board should secure access to and uptake of value-priced medicines, with input and agreement from the devolved nations. The ABPI agrees with the Government that value-based pricing should be reserved for new medicines and indications launched after 1 January 2014.
展开▼
